Search Results - "Lugtenburg, P."

Treatment of Older Patients with Mantle-Cell Lymphoma by Kluin-Nelemans, H.C, Hoster, E, Hermine, O, Walewski, J, Trneny, M, Geisler, C.H, Stilgenbauer, S, Thieblemont, C, Vehling-Kaiser, U, Doorduijn, J.K, Coiffier, B, Forstpointner, R, Tilly, H, Kanz, L, Feugier, P, Szymczyk, M, Hallek, M, Kremers, S, Lepeu, G, Sanhes, L, Zijlstra, J.M, Bouabdallah, R, Lugtenburg, P.J, Macro, M, Pfreundschuh, M, Procházka, V, Di Raimondo, F, Ribrag, V, Uppenkamp, M, André, M, Klapper, W, Hiddemann, W, Unterhalt, M, Dreyling, M.H

“…This international prospective study showed that maintenance therapy with rituximab was more effective than interferon alfa in prolonging the duration of…”
Get full text

Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma by Eertink, J. J., Zwezerijnen, G. J. C., Heymans, M. W., Pieplenbosch, S., Wiegers, S. E., Dührsen, U., Hüttmann, A., Kurch, L., Hanoun, C., Lugtenburg, P. J., Barrington, S. F., Mikhaeel, N. G., Ceriani, L., Zucca, E., Czibor, S., Györke, T., Chamuleau, M. E. D., Hoekstra, O. S., de Vet, H. C. W., Boellaard, R., Zijlstra, J. M.

“…•Baseline 18F-FDG–PET radiomics features can select patients at high risk more accurately than the IPI risk score.•The clinical PET model that was developed in…”
Get full text

Intensified alemtuzumab–CHOP therapy for peripheral T-cell lymphoma by Kluin-Nelemans, H.C., van Marwijk Kooy, M., Lugtenburg, P.J., van Putten, W.L.J., Luten, M., Oudejans, J., van Imhoff, G.W.

“…The prognosis of T-cell lymphoma is poor. To explore the addition of the monoclonal antibody alemtuzumab, we studied the efficacy and tolerability of an…”
Get full text

Primary therapy and survival in patients with Burkitt lymphoma in The Netherlands: a population-based study, 1989-2018 by Issa, D.E., Seefat, R.L., Visser, O., Zweegman, S., Lugtenburg, P.J., Dinmohamed, A.G., Chamuleau, M.E.D.

Get full text

Differences in baseline PET/CT lymphoma distribution patterns between DLBCL‐NOS and high‐risk DLBCL patients by Croese, K. J., Zwezerijnen, G. J. C., Bes, A. L., Wiegers, S. E., Heymans, M. W., Boellaard, R., Lugtenburg, P. J., Eertink, J. J., Zijlstra, J. M., Chamuleau, M. E. D.

Get full text

Aberrant patterns of PET response during treatment for DLBCL patients with MYC gene rearrangements by Eertink, J. J., Arens, A. I. J., Huijbregts, J. E., Celik, F., de Keizer, B., Stroobants, S., de Jong, D., Wiegers, S. E., Zwezerijnen, G. J. C., Burggraaff, C. N., Boellaard, R., de Vet, H. C. W., Hoekstra, O. S., Lugtenburg, P. J., Chamuleau, M. E. D., Zijlstra, J. M.

“…Purpose MYC gene rearrangements in diffuse large B-cell lymphoma (DLBCL) patients are associated with poor prognosis. Our aim was to compare patterns of 2[ 18…”
Get full text

Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients by Eertink, J.J., Burggraaff, C.N., Heymans, M.W., Dührsen, U., Hüttmann, A., Schmitz, C., Müller, S., Lugtenburg, P.J., Barrington, S.F., Mikhaeel, N.G., Carr, R., Czibor, S., Györke, T., Ceriani, L., Zucca, E., Hutchings, M., Kostakoglu, L., Loft, A., Fanti, S., Wiegers, S.E., Pieplenbosch, S., Boellaard, R., Hoekstra, O.S., Zijlstra, J.M., de Vet, H.C.W.

“…Interim 18F-fluorodeoxyglucose positron emission tomography (Interim-18F-FDG-PET, hereafter I-PET) has the potential to guide treatment of patients with…”
Get full text

Cost-Effectiveness of Shortening Treatment Duration Based on Interim PET Outcome in Patients With Diffuse Large B-cell Lymphoma by Greuter, MJE, Eertink, JJ, Jongeneel, G, Dührsen, U, Hüttmann, A, Schmitz, C, Lugtenburg, PJ, Barrington, SF, Mikhaeel, NG, Ceriani, L, Zucca, E, Carr, R, Györke, T, Burggraaff, CN, de Vet, HCW, Hoekstra, OS, Zijlstra, JM, Coupé, VMH

“…Guideline recommendations for diffuse large-B-cell lymphoma (DLBCL) treatment are shifting from long to short treatment duration, although it is still unclear…”
Get full text

R‐CODOX‐M/R‐IVAC VERSUS DA‐EPOCH‐R IN PATIENTS WITH NEWLY DIAGNOSED HIGH‐RISK BURKITT LYMPHOMA: FINAL RESULTS OF A MULTI‐CENTER RANDOMIZED HOVON/SAKK TRIAL by Chamuleau, M., Stenner, F., Chitu, D., Novak, U., Minnema, M., Visser, O., Stevens, W., Zenz, T., Imhoff, G., Wu, K., Demandt, A., Kersten, M. J., Terpstra, W., Tick, L., Deeren, D., Neste, E., Gregor, M., Veelken, H., Bohmer, L., Casper, C., Dirnhofer, S., Brand, M., Jong, D., Nijland, M., Lugtenburg, P.

Get full text

SUBCUTANEOUS EPCORITAMAB INDUCES DEEP, DURABLE COMPLETE REMISSIONS IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA: LONGER FOLLOW‐UP FROM THE PIVOTAL EPCORE NHL‐1 TRIAL by Thieblemont, C., Karimi, Y., Jurczak, W., Cheah, C. Y., Clausen, M. R., Cunningham, D., Do, Y. R., Lewis, D. J., Gasiorowski, R., Kim, T. M., Poel, M., Poon, M. L., Feldman, T., Linton, K. M., Sureda, A., Hutchings, M., Cottereau, A., Al Tabaa, Y., Stirner, M. Cota, Liu, Y., Kilavuz, N., Sacchi, M., Lugtenburg, P., Ghesquieres, H.

Get full text

PHASE 3 TRIAL (GCT3013‐05) OF EPCORITAMAB VERSUS STANDARD OF CARE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) by Thieblemont, C., Clausen, M. R., Balari, A. S., Zinzani, P. L., Fox, C. P., Kim, S. Y., Vindelov, S. D., Lugtenburg, P.

Get full text

Anti-müllerian hormone as a marker of ovarian function in women after chemotherapy and radiotherapy for haematological malignancies by Lie Fong, S., Lugtenburg, P.J., Schipper, I., Themmen, A.P.N., de Jong, F.H., Sonneveld, P., Laven, J.S.E.

“…BACKGROUND In female cancer survivors, the accelerated loss of primordial follicles as a result of gonadal damage may lead to premature ovarian failure (POF)…”
Get full text

POPULATION‐BASED STUDY ON DIFFERENT REGIMENS OF R‐CHOP IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA IN THE NETHERLANDS SUPPORTS THE USE OF 6 CYCLES OF R‐CHOP21 by Issa, D., Dinmohamed, A., Wondergem, M., Blommestein, H., Huijgens, P., Lugtenburg, P., Visser, O., Zweegman, S., Chamuleau, M.

Get full text

Swelling of the breast after cosmetic augmentation by van 't Hart, W, Jansen, A J G, Lam, K H, Lugtenburg, P J, Vasilic, D

Get full text

P1213: SUBCUTANEOUS EPCORITAMAB WITH GEMOX INDUCED HIGH RESPONSE RATES IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA INELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT by Wahlin, B. E., Brody, J., Phillips, T., Costello, R., Lugtenburg, P., Cordoba, R., Wang, L., Wu, J., Elliott, B., Abbas, A., Jørgensen, J.

Get full text

A longitudinal and cross-sectional study ofEpstein-Barr virus DNA load: a possible predictor of AIDS-related lymphoma in HIV-infected patients by Hijlkema, S. H., van Kampen, J. J. A., Voermans, J. J. C., den Oudsten, M. Y. E., Doorduijn, J., van Lugtenburg, P. J., van de Vijver, D. A. M. C., van der Ende, M. E.

“…Introduction: HIV-infected patients are more than 100-fold greater at risk for developing malignant AIDS-related lymphoma (ARL) compared to the general…”
Get full text

Patients' decision‐making, experiences and preferences regarding Pixantrone treatment in relapsed aggressive B‐cell lymphoma: Research protocol for a longitudinal qualitative study by Hoogdalem, L.E., Siemes, C., Lugtenburg, P., Busschbach, J., Ismail, S.

Get full text

P1462: POPULATION‐BASED REAL WORLD RESULTS OF CD19‐DIRECTED CAR T‐CELL THERAPY FOR PATIENTS WITH RELAPSED OR REFRACTORY LARGE B‐CELL LYMPHOMA: A DUTCH CAR T‐CELL TUMORBOARD EXPERIENCE by Spanjaart, A. M., Pennings, E., Mutsaers, P., Dorp, S., Jak, M., Doesem, J., Boer, J., Vermaat, J., Sijs‐Szabo, A., Poel, M., Kuipers, I., Chamuleau, M., Nijhof, I., Minnema, M., Lugtenburg, P., Meerten, T., Kersten, M. J.

Get full text

Multiple venous aneurysms in a patient with hypereosinophilic syndrome by Malskat, W S J, Racz, E, ten Raa, S, Lugtenburg, P J, Hegt, V Noordhoek, de Maeseneer, M G R

“…Hypereosinophilic syndrome (HES) is a diverse group of rare disorders, defined by persistent peripheral blood eosinophilia (>1500 per mm(3)), the absence of a…”
Get more information

RITUXIMAB MAINTENANCE FOR PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA IN FIRST COMPLETE REMISSION: RESULTS FROM A RANDOMIZED HOVON‐NORDIC LYMPHOMA GROUP PHASE III STUDY by Lugtenburg, P., Nully Brown, P., Holt, B., d'Amore, F., Koene, H., Jongh, E., Fijnheer, R., Loosveld, O., Böhmer, L., Pruijt, H., Verhoef, G., Hoogendoorn, M., Bilgin, Y., Nijland, M., Lam, K., Keizer, B., Jong, D., Zijlstra, J.

Get full text